Berberine

Berberine is an isoquinoline alkaloid found in plants like barberry and goldenseal. It has earned a reputation as a "natural statin" because of its consistent effect on LDL cholesterol. That reputation holds up for cholesterol. The more dramatic claims, especially about reversing arterial plaque, do not.

What berberine does to cholesterol

Berberine lowers LDL cholesterol by about 15-16% in placebo-controlled trials, even without changes to diet or exercise [1]. That figure comes from a placebo-controlled meta-analysis, which makes it one of the stronger pieces of evidence on this page. Verhoeven's analysis reaches the same conclusion [2].

Berberine has also been reported to reduce apoB-containing particles, the lipoprotein count that many cardiologists now consider a better marker of cardiovascular risk than LDL alone [2]. Keep in mind this apoB claim rests on Verhoeven's synthesis rather than a separately verified primary trial, so treat it as suggestive rather than settled.

The TMAO signal

TMAO (trimethylamine N-oxide) is a gut-derived metabolite that has been linked to cardiovascular risk. Berberine appears to interfere with its production. In a study including both humans and hamsters, berberine inactivated gut choline TMA-lyase, the enzyme that converts choline and L-carnitine into TMA, and lowered blood TMA/TMAO by more than 30% over four months [3].

A falling TMAO level is a mechanistic signal, not a proven clinical benefit. TMAO's causal role in human atherosclerosis remains contested, so lowering it tells you something is happening biochemically without telling you a patient's arteries will fare better [4].

Why the plaque-reversal claim doesn't hold

The widely repeated idea that berberine reverses arterial plaque traces back to a single study, and that study was open-label, non-randomized, and ran only four months [5]. It is the same paper that produced the TMAO result. Berberine almost reached statistical significance for carotid intima-media thickness (CIMT, a measure of arterial wall thickness), but fell short. The statin comparison arm had no control group and was not randomized [5]. The paper is real; its design cannot support a plaque-reversal claim.

A separate problem surfaced in Verhoeven's review. A meta-analysis of 13 IMT studies that is sometimes cited for berberine turned out to be largely unverifiable: roughly 70% of its constituent studies could not be located [2].

The honest reading: berberine's effects on LDL and TMAO are supported by primary literature, while plaque reversal is not established.

Dosing and absorption

Trials reviewed by Verhoeven used 1-000 mg per day of berberine HCl, split into 500 mg at breakfast and 500 mg at dinner, with no serious adverse effects reported at that dose [2]. This describes what studies used, not a recommendation for your own regimen.

Berberine is poorly absorbed when taken by mouth. Phytosome formulations claim better absorption, but no head-to-head dosing trials were reviewed here, so there is no reliable basis to compare them against standard berberine HCl.

Where the evidence is contested

Two questions remain open.

The first is whether lowering TMAO matters clinically. Berberine clearly reduces TMAO in the one verified study [3], but TMAO's causal role in human atherosclerosis is itself disputed. Some researchers treat TMAO as a driver of cardiovascular disease; others view it as a marker that travels alongside risk without causing it. Until that question is resolved, a TMAO drop should be read as a mechanistic clue, not an outcome [4].

The second is plaque regression. Supporters point to the near-significant CIMT finding as a promising early signal [5]. The design argues against drawing conclusions from it: no randomization, no proper control for the statin arm, and a short four-month window. The supporting meta-analysis is unverifiable because most of its underlying studies cannot be found [2]. On current evidence, plaque reversal is a hypothesis, not a demonstrated effect.

This article is educational and is not medical advice. Decisions about supplements belong in a conversation with your clinician, especially if you already take cholesterol-lowering medication.

References

1. Berberine LDL-C meta-analysis (placebo-controlled) · PubMed 36941490
2. raw/physionic/physionic-berberine-shrinks-plaque-study.txt
3. Berberine → TMAO reduction >30% (human + hamster) · PubMed 35794102
4. raw/physionic/physionic-berberine-tmao*.txt
5. Berberine vs. statin plaque regression (open-label, 4-month) · PubMed 35794102